Clemens Kratochwil1, Frank Bruchertseifer2, Frederik L Giesel3, Mirjam Weis2, Frederik A Verburg4, Felix Mottaghy4, Klaus Kopka5, Christos Apostolidis2, Uwe Haberkorn3, Alfred Morgenstern2. 1. Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany clemens.kratochwil@med.uni-heidelberg.de. 2. European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, Germany. 3. Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. 4. Department of Nuclear Medicine, RWTH University Hospital Aachen, Aachen, Germany; and. 5. Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany.
Abstract
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide-labeled PSMA ligand. Although the case series is still ongoing, we here report in advance about two patients in highly challenging clinical situations who showed a complete response to 225Ac-PSMA-617 therapy. METHODS: 68Ga-PSMA-11 PET/CT validated the presence of the PSMA-positive tumor phenotype. A 100-kBq activity of 225Ac-PSMA-617 per kilogram of body weight was administered bimonthly. Prostate-specific antigen response and hematologic toxicity were measured at least every 4 wk. Restaging was performed with 68Ga-PSMA-11 PET/CT. RESULTS: Both patients experienced a prostate-specific antigen decline to below the measurable level and showed a complete response on imaging. No relevant hematologic toxicity was observed. Xerostomia was the only mentionable clinical side effect. CONCLUSION: Targeted α-therapy with 225Ac-PSMA-617, although still experimental, obviously has strong potential to significantly benefit advanced-stage prostate cancer patients.
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide-labeled PSMA ligand. Although the case series is still ongoing, we here report in advance about two patients in highly challenging clinical situations who showed a complete response to 225Ac-PSMA-617 therapy. METHODS: 68Ga-PSMA-11 PET/CT validated the presence of the PSMA-positive tumor phenotype. A 100-kBq activity of 225Ac-PSMA-617 per kilogram of body weight was administered bimonthly. Prostate-specific antigen response and hematologic toxicity were measured at least every 4 wk. Restaging was performed with 68Ga-PSMA-11 PET/CT. RESULTS: Both patients experienced a prostate-specific antigen decline to below the measurable level and showed a complete response on imaging. No relevant hematologic toxicity was observed. Xerostomia was the only mentionable clinical side effect. CONCLUSION: Targeted α-therapy with 225Ac-PSMA-617, although still experimental, obviously has strong potential to significantly benefit advanced-stage prostate cancerpatients.
Authors: Ganesan Vaidyanathan; Choong Mo Kang; Darryl McDougald; Il Minn; Mary Brummet; Martin G Pomper; Michael R Zalutsky Journal: Nucl Med Biol Date: 2018-05-05 Impact factor: 2.408
Authors: Simona Malaspina; Ugo De Giorgi; Jukka Kemppainen; Angelo Del Sole; Giovanni Paganelli Journal: Radiol Med Date: 2018-08-16 Impact factor: 3.469
Authors: Mike M Sathekge; Frank Bruchertseifer; Ismaheel O Lawal; Mariza Vorster; Otto Knoesen; Thabo Lengana; Tebatso G Boshomane; Kgomotso K Mokoala; Alfred Morgenstern Journal: Eur J Nucl Med Mol Imaging Date: 2019-05-21 Impact factor: 9.236
Authors: Christos Sachpekidis; P Bäumer; K Kopka; B A Hadaschik; M Hohenfellner; A Kopp-Schneider; U Haberkorn; A Dimitrakopoulou-Strauss Journal: Eur J Nucl Med Mol Imaging Date: 2018-01-23 Impact factor: 9.236
Authors: Outi Keinänen; James M Brennan; Rosemery Membreno; Kimberly Fung; Kishore Gangangari; Eric J Dayts; Carter J Williams; Brian M Zeglis Journal: Mol Pharm Date: 2019-09-09 Impact factor: 4.939
Authors: Sophie Poty; Lukas M Carter; Komal Mandleywala; Rosemery Membreno; Dalya Abdel-Atti; Ashwin Ragupathi; Wolfgang W Scholz; Brian M Zeglis; Jason S Lewis Journal: Clin Cancer Res Date: 2018-10-23 Impact factor: 12.531
Authors: Kara M Harmatys; Marta Overchuk; Juan Chen; Lili Ding; Ying Chen; Martin G Pomper; Gang Zheng Journal: Bioconjug Chem Date: 2018-10-29 Impact factor: 4.774